Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Tributyrin (ProButyrate) is a stable butyric acid derivative that releases butyrate in the colon to nourish colonocytes and support gut barrier function. It works by delivering butyrate directly to colonic epithelial cells, where it serves as the primary energy source and regulates inflammatory responses.
Reported Benefits (Provisional)
Origin & History
Tributyrin is a triglyceride composed of three butyrate molecules attached to a glycerol backbone. It is naturally found in butter and is produced industrially for supplementation through esterification processes. ProButyrate is a specialized form designed for enhanced delivery of butyrate to the gut.
Research Narrative (Provisional)
Tributyrin has been the subject of research for its potential to deliver butyrate more effectively to the colon, with studies indicating benefits for gut health and inflammation reduction.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Tributyrin (ProButyrate) is a triglyceride ester composed of three butyrate molecules bound to a glycerol backbone. Macronutrient profile: primarily fat-based (~9 kcal/g), with no significant protein or carbohydrate content. Bioactive compounds: Butyrate (~68-70% by molecular weight), released as free butyric acid (C4:0) upon enzymatic hydrolysis by pancreatic lipases and intestinal esterases; glycerol backbone (~10-12% by weight) released as a metabolic substrate. Butyrate concentration per typical serving (300-600 mg tributyrin): approximately 200-420 mg bioavailable butyrate. Key bioactive roles: short-chain fatty acid (SCFA) acting as primary energy substrate for colonocytes (~60-70% of colonocyte energy demand); histone deacetylase (HDAC) inhibitor at micromolar concentrations (IC50 ~2-5 mM intracellularly); G-protein coupled receptor (GPR41, GPR43, GPR109A) agonist. Bioavailability notes: Tributyrin demonstrates significantly superior bioavailability compared to sodium butyrate (~4-6x greater colonic delivery); protected from upper GI degradation and odor due to esterified form; hydrolysis occurs progressively through small intestine into colon, enabling sustained-release butyrate delivery; oral bioavailability estimated at 70-85% of administered dose reaching target colonic tissue. Micronutrients: negligible mineral or vitamin content inherent to the compound itself.
Reported Mechanism (Provisional)
Tributyrin releases butyrate through enzymatic hydrolysis by pancreatic and intestinal lipases in the small intestine and colon. Butyrate activates G-protein coupled receptors GPR41 and GPR43, inhibits histone deacetylases (HDACs), and serves as the primary fuel source for colonocytes. This process strengthens tight junction proteins like claudin-1 and occludin while promoting regulatory T-cell differentiation through epigenetic modifications.
Clinical Narrative (Provisional)
Human studies on tributyrin supplementation are limited, with most research conducted in animal models and in vitro studies. A small pilot study (n=24) showed tributyrin improved gut barrier function markers after 4 weeks of supplementation. Animal studies demonstrate significant reductions in colonic inflammation and improved insulin sensitivity with doses equivalent to 500-1000mg daily in humans. More robust clinical trials are needed to establish definitive therapeutic benefits and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.